Clinical trials: Behaviour
Nicotine Dependence, Other Tobacco Product, Tobacco Use
Identify Biomarkers of Tobacco Exposure and Nicotine Uptake From JUUL 5% in Adult Smokers
The JUUL 5% Electronic Nicotine Delivery System (ENDS) is being studied as an alternative to combustible cigarette use. This study aims to find out how much nicotine is in the blood and urine of healthy adult subjects after using…
- Conditions
- Nicotine Dependence, Other Tobacco Product, Tobacco Use, Smoking, Tobacco
- Trial name
- Diamond (NCT03463837)
- Testing
- Treatment with JUUL 5%, Virginia Tobacco, Treatment with JUUL 5%, Cool Mint, ENDS, Treatment with JUUL 5%, Mango, ENDS
- Where
- United States
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Juul Labs, Inc.
Major Depression
Safety, Tolerability and Efficacy of the Transdermal System in Elderly Subjects With Major Depression
Objective of this 16-week, open-label study is to assess the safety and tolerability of once daily application of three doses of STS during continuous dosing in the treatment of elderly subjects with major depression.
- Trial name
- NCT00285766
- Testing
- Selegiline Transdermal System
- Where
- 15 sites in United States
- Volunteers
- 300 people
- Sponsor
- Somerset Pharmaceuticals
Major Depressive Disorder
A Trial of the Safety and Efficacy of SEP-363856 in the Treatment of Adults With Major Depressive Disorder
Demonstrate ability of SEP-363856 to be superior to placebo as an adjunctive therapy to ADT in change from baseline in depressive symptoms (MADRS \& CGI-S) in MDD patients who had an inadequate response to prior ADT therapy.
- Trial name
- NCT05593029
- Testing
- SEP-363856
- Where
- 77 sites in United States, Bulgaria and 5 more
- Volunteers
- 929 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Depressive Disorder
An Eight-Week Study Evaluating the Efficacy and Tolerability of Two Doses of SSR149415 in Outpatients With Major Depressive Disorder
The objective is to evaluate the efficacy and safety of two doses of SSR149415 (250 mg and 100 mg twice daily) compared to placebo and escitalopram 10 mg once daily in outpatients with major depressive disorder.
- Trial name
- NCT00358631
- Testing
- SSR149415
- Where
- United States
- Volunteers
- 319 people
- Sponsor
- Sanofi
ADHD, Anxiety
P3b Short-term Study of CTN in Patients With ADHD and Comorbid Anxiety
Primary: To evaluate the efficacy of CTN in adults ages with ADHD and comorbid anxiety (AISRS) Key Secondary: To assess the efficacy of CTN in adults ages with ADHD and comorbid anxiety
- Conditions
- ADHD, Anxiety, Generalized Anxiety, Social Anxiety Disorder
- Trial name
- NCT06973577
- Testing
- Centanafadine
- Where
- 47 sites in United States, Puerto Rico
- Volunteers
- 315 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Tobacco Dependence
Multiple-dose Nicotine Pharmacokinetics With Three Oral Nicotine Replacement Products
Multiple-dose nicotine pharmacokinetics with three oral nicotine replacement products. A study in healthy smokers.
- Trial name
- NCT01321931
- Testing
- Nicotine
- Where
- Sweden
- Volunteers
- 50 people
- Sponsor
- McNeil AB
Depressive Disorder, Major
A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder
The purpose of this study is to evaluate how well JNJ-54135419 works (efficacy) in addition to comprehensive standard of care (SoC) in rapidly reducing the symptoms of major depressive disorder (MDD, a mental disorder…
- Trial name
- AVENUE (NCT07227454)
- Testing
- Esketamine, Midazolam
- Where
- 49 sites in United States, Brazil and 5 more
- Volunteers
- 258 people
- Sponsor
- Janssen Research & Development, LLC
Attention-Deficit/Hyperactivity Disorder
Open-label Study to Evaluate Long-term Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule)
Open label extension, long-term multicenter study of safety and efficacy of SPN-812 in pediatric ADHD patients
- Trial name
- NCT02736656
- Testing
- SPN-812
- Where
- 16 sites in United States
- Volunteers
- 1,400 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
Major Depressive Disorder, Depression
TC-5214 as add-on the Treatment of Major Depressive Disorder
This is a multi-center, double blind, randomized, placebo-controlled, parallel group, flexible dose titration study conducted in centers in the USA and India.
- Trial name
- NCT00692445
- Testing
- TC-5214 + citalopram
- Where
- 27 sites in United States, India
- Volunteers
- 574 people
- Sponsor
- Targacept Inc.
Bipolar Disorder, Depression
Study of the Efficacy of a Fixed-dose Regimen of Cariprazine Compared to Placebo for Treatment of the Depressive Episode in Participants With Bipolar I Disorder
This study is designed to prospectively confirm the efficacy of a fixed-dose regimen of cariprazine 1.5 milligrams (mg)/day or 3 mg/day compared to placebo for treatment of the depressive episode in participants with bipolar I…
- Trial name
- NCT02670538
- Testing
- Cariprazine
- Where
- 89 sites in United States, Bulgaria and 6 more
- Volunteers
- 493 people
- Sponsor
- Forest Laboratories
Major Depressive Disorder (MDD), Major Depressive Disorder With Anxious Distress
A Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study)
This is a randomized, parallel-group, double-blind, placebo-controlled, monotherapy study to evaluate the efficacy, safety, and tolerability of SPT-300 (GlyphAllo) in adults with major depressive disorder (MDD), with or without…
- Trial name
- NCT07065240
- Testing
- SPT-300
- Where
- 61 sites in United States, Bulgaria and 5 more
- Volunteers
- 360 people
- Sponsor
- Seaport Therapeutics
Suicide
CAMS-RAS: for Suicide Prevention
This Phase I feasibility study endeavors to create a prototype of a tool to determine its feasibility with suicidal patients in emergency departments (EDs). This is not a clinical trial.
- Trial name
- CAMS-RAS (NCT03072875)
- Testing
- CAMS-RAS
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Evidence-Based Practice Institute, Seattle, WA
ADHD, Attention Difficulties
A Clinical Trial to Assess the Efficacy of a Plant-based Energy Shot on Focus and ADHD-like Symptoms
This is a virtual, single-arm clinical trial that will last 28 days. Participants will drink 1 bottle of Proper Wild energy shot daily and complete questionnaires at baseline, day 1, day 14, and day 28.
- Conditions
- ADHD, Attention Difficulties, Mood, Anxiety
- Trial name
- NCT05857956
- Testing
- Proper Wild energy shot
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Proper Wild, Inc.
Schizophrenia / Schizoaffective Disorder
NST-SPARK Open-Label Phase 1 STTR (IGNITE)
Schizophrenia Spectrum disorders (SSD) are among the most devastating psychiatric disorders. Prominent negative symptoms such as low motivation, anhedonia, asociality, and emotional flattening are experienced by up to 60% of…
- Trial name
- IGNITE (NCT07593456)
- Testing
- NST-SPARK
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- North Shore Therapeutics, Inc.
Gut Inflammation
A1 Versus A2® Milk on the Gastrointestinal Physiology, Symptoms and Cognitive Behaviour for the Preschool Children
This is a multiple-sites, double-blinded, randomized, controlled, parallel-designed, cross-over study among healthy preschoolers with 5 days consumption of A2 or A1 milk to compare the effects on gut inflammation…
- Trial name
- NCT03081845
- Testing
- Oral consumption of milk A1 in study phase 1, Oral consumption of milk A2 in study phase 1, Oral consumption of milk A1 in study phase 2
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- a2 Milk Company Ltd.
To Determine Bioequivalence Under Fasting Conditions
Bioequivalence Study Doxycycline Tablets and Monodox Capsules Under Fasting Conditions
To compare the rate and extent of absorption of doxycycline tablet (Par) versus doxycycline capsule (Monodox)(Oclassen).
- Trial name
- NCT00652795
- Testing
- Doxycycline Monohydrate, Monodox
- Where
- Canada
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Par Pharmaceutical, Inc.
Chronic Pain
Identification of Predictive Factors for observAnce of Transcutaneous Electrical NeuroStimulation (TENS) in Chronic Pain
This is a retrospective and transverse multicenter study to identify predictive factors for adherence to TENS by chronic pain patients followed in structures specialized in Chronic Pain management (SPC).
- Trial name
- IPATENS (NCT04253639)
- Testing
- Questionnaires
- Volunteers
- 500 people
- Sponsor
- Sublimed
Chronic Obstructive Pulmonary Disease
QVA Mechanistic Efficacy Study (Receptor Effects, Etc)
The purpose of this study was to assess global ventilated lung volume in moderate to severe COPD patients using MRI lung imaging after treatment with QVA149 compared to placebo.
- Trial name
- NCT02634983
- Testing
- QVA149
- Where
- 3 sites in United Kingdom
- Volunteers
- 31 people
- Sponsor
- Novartis Pharmaceuticals
Attention Deficit Hyperactivity Disorder
Safety and Efficacy of GTS21 in Adults With Attention-deficit Hyperactivity Disorder
This study will be a randomized, double-blind, placebo-controlled crossover study to assess the effects of GTS21 (25 mg three times a day (tid), 75 mg tid, 150 mg tid) compared to placebo in non-smoking adults aged 18-55 with a…
- Trial name
- NCT00419445
- Where
- 2 sites in United States
- Volunteers
- 37 people
- Sponsor
- CoMentis
Smoking
Reduced Exposure Study Using THS 2.2 Menthol With 5 Days in a Confinement Setting and 85 Days in an Ambulatory Setting
The main goal of the study is to evaluate if the ad libitum use of the THS 2.2 Menthol (mTHS 2.2) for 5 days in confinement and after 85 days of product use in an ambulatory setting, by Japanese adult healthy smokers results in a…
- Trial name
- NCT01970995
- Testing
- THS 2.2 Menthol (mTHS 2.2), Smoking Abstinence (SA), Menthol Conventional Cigarette (mCC)
- Where
- Japan
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- Philip Morris Products S.A.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.